


**A**

Estimated New Cases


Prostate	313,780	30%
Lung & bronchus	110,680	11%
Colon & rectum	82,460	8%
Urinary bladder	65,080	6%
Melanoma of the skin	60,550	6%
Kidney & renal pelvis	52,410	5%
Non-Hodgkin lymphoma	45,140	4%
Oral cavity & pharynx	42,500	4%
Leukemia	38,720	4%
Pancreas	34,950	3%



Breast	316,950	32%
Lung & bronchus	115,970	12%
Colon & rectum	71,810	7%
Uterine corpus	69,120	7%
Melanoma of the skin	44,410	4%
Non-Hodgkin lymphoma	35,210	4%
Pancreas	32,490	3%
Thyroid	31,350	3%
Kidney & renal pelvis	28,570	3%
Leukemia	28,170	3%

Estimated Deaths

Lung & bronchus	64,190	20%
Prostate	35,770	11%
Colon & rectum	28,900	9%
Pancreas	27,050	8%
Liver & intrahepatic bile duct	19,250	6%
Leukemia	13,500	4%
Esophagus	12,940	4%
Urinary bladder	12,640	4%
Non-Hodgkin lymphoma	11,060	3%
Brain & other nervous system	10,170	3%



Lung & bronchus	60,540	21%
Breast	42,170	14%
Pancreas	24,930	8%
Colon & rectum	24,000	8%
Uterine corpus	13,860	5%
Ovary	12,730	4%
Liver & intrahepatic bile duct	10,840	4%
Leukemia	10,040	3%
Non-Hodgkin lymphoma	8,330	3%
Brain & other nervous system	8,160	3%

Estimates exclude US territories and are rounded to the nearest 10; cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Ranking is based on modeled projections and may differ from observed data.

©2025, American Cancer Society, Inc., Surveillance and Health Equity Science